Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Alector expects the partnership to fund operations into 2029 while retaining its brain-delivery platform for its wholly owned pipeline.

Rhea-AI Summary

Alector (Nasdaq: ALEC) entered an exclusive global licensing agreement with Genentech for AL050, with a $100 million upfront payment. AL050 is an investigational enzyme replacement therapy for Parkinson’s disease and other neurodegenerative diseases that uses Alector Brain Carrier (ABC) to deliver engineered GCase into the brain. Alector is eligible for up to $1.17 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.

Genentech will handle development, regulatory activities, manufacturing and commercialization across all indications. Alector retains ABC ownership and full rights to use it across its wholly owned pipeline. Alector expects the partnership to extend its cash runway into 2029, supporting its anti-Aβ antibody through multi-cohort clinical data in Alzheimer’s patients and its tau and alpha-synuclein siRNA programs through studies needed for investigational new drug filings.

8 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointAL050 licensing agreement provides Alector a $100 million upfront payment from Genentech. 49% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Additional milestone payments offer Alector potential receipts of up to $1.17 billion.
• Minor point. Forward-looking: it has not happened yet and may not happen.Tiered royalties on net sales provide additional potential payments to Alector.
• Minor pointGenentech assumes development, regulatory, manufacturing and commercialization responsibilities across all indications.
• Minor pointABC ownership and full pipeline rights remain with Alector.

3 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.Alector expects the partnership to extend its cash runway into 2029.
• Minor point. Forward-looking: it has not happened yet and may not happen.Alector plans to advance its anti-Aβ antibody to multi-cohort clinical data in Alzheimer’s patients.
• Minor point. Forward-looking: it has not happened yet and may not happen.Alector plans to advance tau and alpha-synuclein siRNA programs through enabling studies to investigational new drug filings.

Negative

• Minor pointAdditional milestone payments depend on achieving development, regulatory and commercial milestones.

Argus 15 min delay 10 alerts

+16.02% vs previous close $2.10 last price 2.7x rel. volume Open Argus

Details

Market Reaction – ALEC

+3.8% Peak in 0 min

$2.10 – $2.72 Day Range

$234.48M Market Cap

On Oct 5, the day this news came out, the latest delayed price for ALEC is 16.02% above the previous close. Argus tracked a peak move of +3.8% during the session. Our momentum scanner has recorded 10 alerts for this stock so far that day. The latest delayed price is $2.10. Relative volume is elevated at 2.7x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Upfront payment: $100 million Potential milestone payments: Up to $1.17 billion Cash runway: Into 2029

Upfront payment

$100 million

Global AL050 license agreement

Potential milestone payments

Up to $1.17 billion

Contingent on development, regulatory, and commercial milestones

Cash runway

Into 2029

Company says the partnership extends its cash runway

Historical Context

1 past event · Latest: Aug 06

1 event

1. Aug 06

   AL050 pipeline update

   24h Move

   -2.7%

   Reported AL050 preclinical activity and safety signals supporting continued development before Genentech licensing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

enzyme replacement therapy (ert), blood-brain barrier, glucocerebrosidase (gcase), gba1 mutations, +2 more

6 terms

enzyme replacement therapy (ert) medical

"AL050, an investigational GCase Enzyme Replacement Therapy (ERT)"

Enzyme replacement therapy (ERT) is a medical treatment that supplies a missing or defective enzyme a patient’s body cannot make, restoring a chemical process much like adding the right tool to a broken machine so it can run again. For investors, ERT matters because successful therapies can create sustained revenue streams, affect regulatory risk and reimbursement decisions, and change the market value of companies developing, manufacturing, or distributing these specialized biologic drugs.

blood-brain barrier medical

"designed to transport therapeutics across the blood-brain barrier"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

glucocerebrosidase (gcase) medical

"brain-penetrant engineered glucocerebrosidase (GCase) ERT"

Glucocerebrosidase (GCase) is a naturally occurring enzyme that helps cells break down a specific fatty molecule inside their internal “recycling centers”; if GCase activity is low, that fat can accumulate and harm cells. Investors pay attention because genetic changes or reduced GCase function are linked to certain inherited and neurodegenerative diseases, so therapies, tests or trial results targeting GCase can strongly influence biotech valuations and clinical outlooks.

gba1 mutations medical

"most pronounced in – but not limited to – carriers of GBA1 mutations"

Mutations in the GBA1 gene are changes in the DNA sequence of the gene that encodes the enzyme glucocerebrosidase. Certain GBA1 mutations reduce or eliminate that enzyme's activity, causing accumulation of specific lipids in cells; when an individual inherits two disease-causing copies (one from each parent) this causes Gaucher disease, while carrying a single mutated copy is a known genetic risk factor that increases the likelihood of developing Parkinson's disease and related neurodegenerative conditions. Mutations can take several molecular forms (for example missense, nonsense, insertions/deletions) and vary in severity depending on how much they impair enzyme function.

glucosylsphingosine medical

"break down glucosylsphingosine and glucosylceramide"

Glucosylsphingosine is a small fat-like molecule that builds up when a specific cellular cleanup enzyme is not working properly; it acts as a biological signal or biomarker for certain metabolic disorders. For investors, its level is important because it is used in diagnostics, patient monitoring and clinical trials to show whether a therapy is working—think of it as a smoke alarm that helps drug developers and regulators detect and measure disease activity and treatment effects.

glucosylceramide medical

"break down glucosylsphingosine and glucosylceramide"

A glucosylceramide is a glycosphingolipid molecule made of a single glucose sugar attached to a ceramide lipid; it is a common component of cell membranes and a biochemical precursor for more complex glycosphingolipids. In human biology it is produced and broken down by specific enzymes (including glucocerebrosidase), and abnormal accumulation of glucosylceramide in cells is the biochemical hallmark of certain lysosomal storage disorders and a target for specific therapies. As a biochemical species, it participates in membrane structure and cell signaling and is measured or manipulated in drug development and diagnostic contexts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector’s proprietary blood-brain barrier delivery platform

Alector to receive $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered royalties on net sales

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT.

AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson’s Disease that is most pronounced in – but not limited to – carriers of GBA1 mutations. It combines an Alector-engineered GCase, optimized for greater enzymatic activity and a longer half-life, with Alector’s ABC, which is designed to transport therapeutics across the blood-brain barrier. Delivered into the brain, the enzyme is intended to break down glucosylsphingosine and glucosylceramide, lipids that accumulate in neurons and other brain cells upon GCase deficiency and contribute to neurodegeneration, with the aim of reducing cellular dysfunction and slowing disease progression.

“Deficient GCase activity is increasingly recognized as a contributor to Parkinson’s Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain. AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier. Genentech’s long-standing commitment to Parkinson's Disease makes them an ideal partner as this program moves toward the clinic".

"Parkinson's Disease is one of the fastest-growing neurological conditions worldwide," said Boris L. Zaïtra, Head of Roche Corporate Business Development. "By partnering with companies such as Alector we aim to delay or halt the progression of Parkinson's so patients maintain and prolong their independence."

Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Alector is also eligible for tiered royalties on net sales. Under the collaboration, Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications.  Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline.  

"This partnership extends our cash runway into 2029, providing resources to advance our fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer’s patients, and move our subcutaneously delivered, brain-enabled Tau siRNA and alpha- synuclein siRNA programs through IND-enabling studies and to IND filings," said Dr. Rosenthal.

Alector R&D Webinar on Wholly Owned Pipeline

Alector will host a scientific webinar on Tuesday, October 13^th, 2026, at 8:00 a.m. PT, focused on AL137, its brain-enabled anti-Aβ antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program. Registration and webcast information will be available on the Events and Presentations page of the Alector corporate website.

About Alector

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, planned clinical trials, expected milestones, expectations of our collaborations, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (SEC), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.

Alector Contacts

Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com

Argot Partners (investors)
Laura Perry
alector@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What payments can Alector receive under the Genentech AL050 licensing agreement?

Alector will receive $100 million upfront and is eligible for up to $1.17 billion in additional milestone payments, plus tiered royalties on net sales. The additional milestone payments depend on development, regulatory and commercial achievements.

What rights does Genentech receive in Alector’s AL050 agreement?

Genentech receives exclusive worldwide rights to develop and commercialize AL050 and will handle development, regulatory activities, manufacturing and commercialization across all indications. Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline.